BusinessAgile Therapeutics, Inc. Announces Full Exercise of Option to Purchase Additional Shares by UnderwritersBy Nasdaq OMXFeb 4, 2016, 9:10 PM UTC
BusinessEsperion Therapeutics Announces Initiation of Phase 3 Clinical Program With Long-Term Safety and Tolerability StudyBy Nasdaq OMXJan 13, 2016, 1:30 PM UTC
BusinessAquinox Announces Update on Development Program for AQX-1125 Following Meeting With FDABy Nasdaq OMXJan 11, 2016, 12:00 PM UTC
BusinessAgile Therapeutics Receives Approximately $6 Million in Non-Dilutive Funding From New Jersey’s Technology Business Tax Certificate Transfer ProgramBy Nasdaq OMXDec 1, 2015, 12:45 PM UTC
